Table 4.
Variable | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
HR (95%CI) | P value | HR (95%CI) | P value | |
Age | 0.992(0.972~1.013) | 0.449 | ||
Gender | 0.158 | |||
Male | Reference | |||
Female | 0.587(0.280~1.229) | |||
ECOG performance | 0.250 | |||
0 | Reference | |||
1 | 1.319(0.823~2.114) | |||
Number of tumors | 0.001 | 0.044 | ||
>3 | Reference | Reference | ||
≤3 | 3.192(1.570~6.492) | 2.212(1.022~4.790) | ||
HBV infection | 0.463 | |||
No | Reference | |||
Yes | 0.758(0.361~1.589) | |||
Child-Pugh class | 0.210 | |||
A | Reference | |||
B | 0.651(0.333~1.274) | |||
BCLC stage | 0.085 | 0.056 | ||
B | Reference | Reference | ||
C | 1.567(0.939~2.615) | 1.662(0.987~2.797) | ||
Extrahepatic metastases | 0.153 | |||
Yes | Reference | |||
No | 0.845 (0.563~1.351) | |||
AFP (ng/ml) | 0.806 | |||
>400 | Reference | |||
≤400 | 1.063(0.655~1.725) | |||
Tumor size (cm) | 1.005(0.952~1.060) | 0.862 | ||
PLR | 1.000(0.996~1.003) | 0.929 | ||
NLR | 0.904(0.794~1.028) | 0.124 | ||
ALT(IU/L) | 1.001(0.997~1.005) | 0.512 | ||
AST (IU/L) | 1.001(0.992~1.009) | 0.892 | ||
Albumin (g/dL) | 1.040(0.987~1.096) | 0.144 | ||
TB (µmol/L) | 1.019(0.978~1.062) | 0.370 | ||
PT(s) | 1.042(0.956~1.135) | 0.348 | ||
TACE Sessions | 0.971(0.896~1.052) | 0.468 | ||
Treatment | <0.001 | 0.005 | ||
TACE-LEN | Reference | Reference | ||
TACE-LEN-C | 0.351(0.211~0.584) | 0.451(0.259~0.784) |
HR, hazard ratio; CI, confidence interval; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B; AFP, alpha-fetoprotein; ALT, alanine transaminase; AST, aspartate aminotransferase; HCC, hepatocellular carcinoma; PFS, progression-free survival; TACE-LEN, transcatheter arterial chemoembolization with Lenvatinib; TACE-LEN-C, transcatheter arterial chemoembolization with Lenvatinib plus camrelizumab. Bold values signifies important information in the Statistical analysis section.